论文部分内容阅读
头孢噻肟是一个具有广谱、高效、耐酶、低毒性等特点的第三代头孢菌素。国产头孢噻肟由四川抗菌素工业研究所、东北制药总厂、四川长征制药厂共同研制成功,国家医药管理局1985年7月主持了头孢噻肟产品的技术鉴定会。此后,华西医科大学附属医院和重庆医科大学附属医院又对头孢噻肟进行了系统的临床药理与应用研究,于1989年4月4日由四川省卫生厅主持在成都召开了鉴定会。参加这次鉴定会的有省内有关药物研制、药理、临床药理,临床应用等方面的专家20余人。会议听取了由黄安华代表华西医科大学附属医院和王其南教授代表重庆医科大学附属医院所作的国产头孢噻肟的临床药理与应用研究的详细总结报告。经过代表们的充份讨论,认为:
Cefotaxime is a third generation cephalosporin with broad spectrum, high efficiency, resistance to enzymes and low toxicity. Domestic cefotaxime by the Sichuan Institute of antibiotics, Northeast Pharmaceutical Factory, Sichuan Changzheng Pharmaceutical Factory jointly developed successfully, the State Pharmaceutical Administration in July 1985 presided over the cefotaxime product technical appraisal meeting. Since then, Huaxi Medical University Affiliated Hospital and Affiliated Hospital of Chongqing Medical University and cefotaxime conducted a systematic clinical pharmacology and applied research, on April 4, 1989 chaired by the Sichuan Provincial Health Department held in Chengdu identification. To participate in the identification of the province there are about 20 experts in the field of drug development, pharmacology, clinical pharmacology, clinical applications and so on. The meeting listened to a detailed summary report on clinical pharmacology and application research of domestic cefotaxime made by Huang Anhua on behalf of Affiliated Hospital of Huaxi Medical University and Professor Wang Qizhen on behalf of Affiliated Hospital of Chongqing Medical University. After full discussion of the deputies, I think: